Adrian Villalba, Silvia Rodriguez-Fernandez, David Perna-Barrull, Rosa-Maria Ampudia, Laia Gomez-Muñoz, Irma Pujol-Autonell, Eva Aguilera, Ruth M Risueño, Mary Cano-Sarabia, Daniel Maspoch, Federico Vázquez, Marta Vives-Pi
Type 1 diabetes is an autoimmune disease caused by the destruction of the insulin-producing β-cells. To revert type 1 diabetes, the suppression of the autoimmune attack should be combined with a β-cell replacement strategy. It has been previously demonstrated that liraglutide, a glucagon-like peptide-1 receptor agonist, restores β-cell mass in type 1 diabetes, via α-cell transdifferentiation and neogenesis. We report here that treatment with liraglutide does not prevent type 1 diabetes in the spontaneous non-obese diabetic (NOD) mouse model, but it tends to reduce leukocytic islet infiltration...
November 3, 2020: Scientific Reports